Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Lundbeck Rises on Results for Experimental Antidepressant

Don't Miss Out —
Follow us on:

May 14 (Bloomberg) -- H. Lundbeck A/S rose the most in six months after saying an experimental antidepressant showed statistically significant results in three late-stage studies that will support regulatory filings in the U.S. and Europe.

The shares gained 8.8 percent, the biggest gain since Nov. 11, to 118.60 kroner in Copenhagen, where the company is based. The drugmaker is developing the product with Japanese partner Takeda Pharmaceutical Co.

Data from the three studies showed LU AA21004 reduced depression symptoms in a dose range from 10 milligrams to 20 milligrams, compared with placebo, the company said in a statement today. Lundbeck, the Nordic region’s second-largest drugmaker, needs new products to replace lost revenue from antidepressant Lexapro, which goes off-patent in Europe in mid-2014. It plans to submit applications for approval of LU AA21004 in the U.S. and Europe this year. Annual sales for the drug may reach as much as $2 billion, the company has said.

Out of 10 large, placebo-controlled trials trials completed in patients, eight have shown that the drug is effective for depression, Lundbeck said. The most common side effects were nausea, headache, diarrhea and vomiting. Further analysis of the data is expected to be presented at upcoming medical conferences, the company said.

(A conference call will be held tomorrow at 9 a.m. Copenhagen time. Investors will be able to listen in via a link on www.lundbeck.com, which can be found under ‘Investors.’)

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.